^
Association details:
| Biomarker: | MYD88 mutation + CXCR4 mutation |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IBRUTINIB SHOWS PROLONGED PROGRESSION-FREE SURVIVAL IN SYMPTOMATIC, PREVIOUSLY TREATED PATIENTS WITH MYD88 MUTATED WALDENSTROM'S MACROGLOBULINEMIA: LONG-TERM FOLLOW-UP OF PIVOTAL TRIAL (NCT01614821).
Published date:
05/17/2018
Excerpt:
For patients with MYD88MutCXCR4Mut, the median PFS was 42 months (5-year PFS 46%; 95% CI 23-67%), and for those with MYD88WT disease it was 5 months (Log-rank p<0.001) The 5-year overall survival for all patients was 87%, and 93% and 80% for MYD88MutCXCR4WT and MYD88MutCXCR4Mut patients, respectively (Log-rank p=0.41)...ibrutinib is highly active and produces long-term responses in symptomatic patients with relapsed and refractory WM
Trial ID:
Source:
Title:
IBRUTINIB MONOTHERAPY IN SYMPTOMATIC, TREATMENT-NAIVE PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA.
Published date:
05/17/2018
Excerpt:
30 WM patients received ibrutinib. All carried MYD88 mutation, and 14 (47%) CXCR4 mutation....Overall (> minor) and major (> partial) responses for all patients were 100% and 83%, respectively. Major (94% vs. 71%) and very good partial (31 vs. 7%) responses were higher, and time to major responses more rapid (1.8 vs. 7.3 months; p=0.01) in wild-type versus mutated CXCR4 patients, respectively.
